$1.23 Billion is the total value of Cormorant Asset Management, LP's 70 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 18.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Sell | MIRATI THERAPEUTICS INC | $74,307,000 | -12.8% | 1,751,699 | -3.2% | 6.03% | +8.9% |
| ANAB | Sell | ANAPTYSBIO INC | $70,523,000 | -37.7% | 1,105,557 | -2.6% | 5.73% | -22.2% |
| TSRO | Sell | TESARO INC | $66,825,000 | +37.0% | 900,000 | -28.0% | 5.42% | +71.2% |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $40,383,000 | -7.1% | 1,474,362 | -0.8% | 3.28% | +16.1% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $37,217,000 | -31.4% | 3,481,471 | -2.1% | 3.02% | -14.3% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $33,581,000 | +1.0% | 1,422,911 | -8.4% | 2.73% | +26.1% |
| MYOK | Sell | MYOKARDIA INC | $33,100,000 | -27.5% | 677,451 | -3.2% | 2.69% | -9.4% |
| QTNT | Sell | QUOTIENT LTD | $29,148,000 | -20.4% | 4,762,772 | -1.8% | 2.37% | -0.6% |
| TBPH | Sell | THERAVANCE BIOPHARMA INC | $22,645,000 | -37.0% | 884,916 | -19.6% | 1.84% | -21.3% |
| AVRO | Sell | AVROBIO INC | $22,607,000 | -70.8% | 1,357,784 | -9.0% | 1.84% | -63.5% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $21,204,000 | -14.5% | 338,456 | -3.3% | 1.72% | +6.8% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $19,480,000 | -34.3% | 361,351 | -4.9% | 1.58% | -17.9% |
| ZLAB | Sell | ZAI LAB LTDadr | $18,284,000 | +16.1% | 787,426 | -2.6% | 1.48% | +45.1% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $17,980,000 | -78.5% | 547,000 | -60.1% | 1.46% | -73.1% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $17,600,000 | -34.4% | 183,732 | -3.3% | 1.43% | -18.1% |
| SLDB | Sell | SOLID BIOSCIENCES INC | $17,500,000 | -44.7% | 652,987 | -2.6% | 1.42% | -30.9% |
| TCDA | Sell | TRICIDA INC | $17,252,000 | -23.1% | 731,621 | -0.4% | 1.40% | -4.0% |
| INCY | Sell | INCYTE CORP | $15,982,000 | -11.0% | 251,335 | -3.3% | 1.30% | +11.2% |
| INSP | Sell | INSPIRE MED SYS INC | $12,263,000 | -2.9% | 290,239 | -3.3% | 1.00% | +21.3% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $11,685,000 | -38.1% | 300,000 | -26.8% | 0.95% | -22.6% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $8,276,000 | -9.3% | 580,756 | -3.2% | 0.67% | +13.3% |
| NKTR | Sell | NEKTAR THERAPEUTICScall | $8,218,000 | -89.9% | 250,000 | -81.2% | 0.67% | -87.3% |
| RUBY | Sell | RUBIUS THERAPEUTICS INC | $5,803,000 | -33.7% | 360,910 | -1.0% | 0.47% | -17.2% |
| CFRX | Sell | CONTRAFECT CORP | $4,446,000 | -28.4% | 2,905,638 | -3.1% | 0.36% | -10.6% |
| HRTX | Sell | HERON THERAPEUTICS INC | $4,298,000 | -20.1% | 165,682 | -2.5% | 0.35% | -0.3% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $4,213,000 | +14.3% | 245,370 | -1.9% | 0.34% | +42.5% |
| YMAB | Sell | Y MABS THERAPEUTICS INC | $3,961,000 | -25.4% | 194,768 | -2.6% | 0.32% | -6.7% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $3,533,000 | -51.3% | 478,055 | -4.4% | 0.29% | -39.2% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $3,488,000 | -45.5% | 488,534 | -2.3% | 0.28% | -32.0% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $2,597,000 | -47.5% | 121,797 | -2.6% | 0.21% | -34.5% |
| ITRM | Sell | ITERUM THERAPEUTICS PLC | $2,335,000 | -26.9% | 466,002 | -2.3% | 0.19% | -8.7% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $2,230,000 | -34.2% | 194,274 | -2.9% | 0.18% | -17.7% |
| XLRN | Sell | ACCELERON PHARMA INC | $2,121,000 | -25.9% | 48,695 | -2.6% | 0.17% | -7.5% |
| OMER | Sell | OMEROS CORPcall | $2,024,000 | -92.7% | 181,700 | -84.0% | 0.16% | -90.9% |
| ARQL | Sell | ARQULE INC | $809,000 | -52.4% | 292,095 | -2.6% | 0.07% | -40.0% |
| ONSIW | Exit | ONCOBIOLOGICS INC - CW17 -A*w exp 02/18/201 | $0 | – | -416,666 | -100.0% | -0.00% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -400,000 | -100.0% | -0.16% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -0.19% | – | |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.20% | – |
| AKCA | Exit | AKCEA THERAPEUTICS INCput | $0 | – | -100,000 | -100.0% | -0.23% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.55% | – |
| OMER | Exit | OMEROS CORP | $0 | – | -1,000,000 | -100.0% | -1.59% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -1,326,136 | -100.0% | -2.64% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.